FDA Grants Durvalumab Orphan Drug Status in Small Cell Lung Cancer

July 12, 2019 – The FDA has granted an Orphan Drug Designation to durvalumab for the treatment of patients with small cell lung cancer (SCLC), according to AstraZeneca, the developer of the PD-L1 inhibitor. The designation follows the announcement of the phase III CASPIAN trial data, in which the combination of durvalumab and standard etoposide and platinum-based chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival … (leggi tutto)